Ardsley Advisory Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Ardsley Advisory Partners’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-102,500	Closed	-$5.41M	–	190
2018 Q1	$5.41M	Sell	102,500 -2,000	-2%	-$117K	0.81%	42
2017 Q4	$7.11M	Sell	104,500 -8,000	-7%	-$559K	0.86%	31
2017 Q3	$9.27M	Buy	+112,500	New	+$8.92M	1.23%	28
2014 Q1	–	Sell	-7,000	Closed	-$422K	–	279
2013 Q4	$422K	Buy	+7,000	New	+$381K	0.06%	101

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Ardsley Advisory Partners's CLVS Position: Q2 2018 in Review

Ardsley Advisory Partners sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 102,500 shares — an estimated $5.41M sold.

Ardsley Advisory Partners first reported a position in CLVS in Q4 2013 and held it in 4 quarters. The position peaked at $9.27M in Q3 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

Ardsley Advisory Partners reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 102,500 Clovis Oncology, Inc. shares in Q2 2018, an estimated $5.41M.
Ardsley Advisory Partners first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 4 quarters.
Ardsley Advisory Partners's Clovis Oncology, Inc. position peaked at $9.27M in Q3 2017.
210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on Ardsley Advisory Partners's 13F filing for Q2 2018, filed 14 Aug 2018.